These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 35313912)
1. Antimicrobial activity of ceftazidime-avibactam and comparators against levofloxacin-resistant Escherichia coli collected from four geographic regions, 2012-2018. Stone GG; Hackel MA Ann Clin Microbiol Antimicrob; 2022 Mar; 21(1):13. PubMed ID: 35313912 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017). Ko WC; Stone GG Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program. Jia P; Zhu Y; Zhang H; Cheng B; Guo P; Xu Y; Yang Q BMC Microbiol; 2022 Oct; 22(1):234. PubMed ID: 36182895 [TBL] [Abstract][Full Text] [Related]
5. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators Against Fluoroquinolone-Resistant Kiratisin P; Arhin FF; Stone G; Utt E Microb Drug Resist; 2022 Nov; 28(11):1019-1027. PubMed ID: 36251881 [TBL] [Abstract][Full Text] [Related]
6. Longitudinal analysis of the in vitro activity of ceftazidime/avibactam versus Enterobacteriaceae, 2012-2016. Ramalheira E; Stone GG J Glob Antimicrob Resist; 2019 Dec; 19():106-115. PubMed ID: 31295583 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ceftazidime/avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017. Stone GG; Ponce-de-Leon A J Antimicrob Chemother; 2020 Jul; 75(7):1859-1873. PubMed ID: 32277820 [TBL] [Abstract][Full Text] [Related]
8. In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014). Nichols WW; de Jonge BL; Kazmierczak KM; Karlowsky JA; Sahm DF Antimicrob Agents Chemother; 2016 Aug; 60(8):4743-9. PubMed ID: 27216074 [TBL] [Abstract][Full Text] [Related]
9. Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Flamm RK; Sader HS; Farrell DJ; Jones RN Diagn Microbiol Infect Dis; 2014 Nov; 80(3):233-8. PubMed ID: 25128477 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of aztreonam/avibactam against a global collection of Klebsiella pneumoniae collected from defined culture sources in 2016 and 2017. Esposito S; Stone GG; Papaparaskevas J J Glob Antimicrob Resist; 2021 Mar; 24():14-22. PubMed ID: 32841721 [TBL] [Abstract][Full Text] [Related]
11. Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015-2017). Rossolini GM; Stone GG Int J Antimicrob Agents; 2020 Sep; 56(3):106111. PubMed ID: 32721602 [TBL] [Abstract][Full Text] [Related]
12. Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015). Sader HS; Huband MD; Duncan LR; Flamm RK Pediatr Infect Dis J; 2018 Jun; 37(6):549-554. PubMed ID: 29206750 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections. Sader HS; Castanheira M; Duncan LR; Mendes RE Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144 [TBL] [Abstract][Full Text] [Related]
15. Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region. Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Snippes Vagnone P; Witwer M; Castanheira M; Johnson JR Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32718965 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of ceftazidime/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018. Kiratisin P; Kazmierczak K; Stone GG J Glob Antimicrob Resist; 2021 Dec; 27():132-141. PubMed ID: 34478880 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Malaysia: Results from the ATLAS Programme, 2013 to 2019. Tuan Soh TS; Salvinder S; Chen VSY Med J Malaysia; 2022 Mar; 77(2):174-184. PubMed ID: 35338624 [TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Sader HS; Castanheira M; Flamm RK; Farrell DJ; Jones RN Antimicrob Agents Chemother; 2014; 58(3):1684-92. PubMed ID: 24379201 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015-2017. Stone GG; Seifert H; Nord CE Int J Antimicrob Agents; 2020 Sep; 56(3):106045. PubMed ID: 32522673 [TBL] [Abstract][Full Text] [Related]